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INTRODUCTION
Histiocytic and dendritic cell neoplasms are a rare group of 
hematologic malignancies. Their cellular origin is the mononu-
clear phagocyte system, including myeloid (stem cell)-derived 
monocytes, monocyte-derived macrophages, monocyte-de-
rived dendritic cells, and stroma (mesenchymal stem cell)-de-
rived dendritic cells.1-3 As the function and phenotype of their 
normal cellular counterparts vary widely, these histiocytic and 
dendritic cell neoplasms are classified into a wide range of 
subtypes. World Health Organization (WHO) classification cat-
egorizes these neoplasms into the following subtypes: tumors 
derived from Langerhans cells, including Langerhans cell his-
tiocytosis (LCH) and Langerhans cell sarcoma (LCS); histio-
cytic sarcoma (HS); indeterminate dendritic cell tumor (IDCT); 
interdigitating dendritic cell sarcoma (IDCS); follicular den-
dritic cell sarcoma (FDCS) and inflammatory pseudotumor-
like follicular/fibroblastic dendritic cell sarcoma; fibroblastic 
reticular cell tumor; disseminated juvenile xanthogranuloma 
(DJG); and Erdheim-Chester disease (ECD), as well as dermal 
xanthogranuloma (dermal XG). LCH accounts for the majori-
ty of cases of histiocytic and dendritic cell neoplasms and is 
thought be a typical form of such neoplasms. Therefore, cases 
with histiocytic and dendritic cell neoplasms are commonly 
divided into LCH and non-LCH groups.2-4
Most histiocytic and dendritic cell neoplasm subtypes are 
of a malignant nature, designated as “malignant neoplasms of 
histiocytes and accessory lymphoid cells” by the WHO.3 How-
ever, the dermal XG and DJG subtypes are considered benign 
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or “uncertain whether benign or malignant” according to the 
International Classification of Disease (ICD)-10 or -11.5,6 Due 
to their relatively low incidence and the wide range of subtypes, 
the epidemiologic and clinical features, outcomes, and prog-
nosis-related factors associated with histiocytic and dendritic 
cell neoplasms have been poorly described. Although some 
recent studies have described their clinicopathological and 
prognostic features, these studies focused on only a single sub-
type, reported results of meta-analyses, or included a relative-
ly small number of LCH and/or other subtypes.7-20 Comprehen-
sive and comparative analyses have rarely been conducted on 
the overall spectrum of histiocytic and dendritic cell neoplasms.
Accordingly, the present study aimed to describe the epide-
miologic features of the entire spectrum of histiocytic and den-
dritic cell neoplasms, including clinicopathological variables 
and patient outcomes.
MATERIALS AND METHODS
Case selection, review, and data acquisition
We retrospectively reviewed the medical records of patients 
diagnosed with histiocytic and dendritic neoplasms at Sever-
ance Hospital (Seoul, South Korea) between 1995 to 2018. The 
exclusion criteria were 1) diagnosis of myeloproliferative neo-
plasm and myelodysplastic syndrome, such as acute mono-
cytic leukemia and blastic plasmacytoid dendritic cell neo-
plasm, and 2) unavailable data from hematoxylin and eosin 
stain slides or immunohistochemistry findings, as well as mo-
lecular test reports. Three pathologists (HM Kim, WI Yang, and 
SO Yoon) reviewed all available hematoxylin and eosin stain 
slides, findings of immunohistochemistry and/or in situ hy-
bridization by routine light microscopy, and the molecular test 
reports. Disagreements in diagnosis were resolved by consen-
sus through a discussion. Details on the diagnostic methods 
used are summarized in Supplementary Materials 1 (only on-
line). When applicable, the results of ancillary studies trans-
ferred from other institutions were used for classification. We 
re-classified diagnoses according to the recently updated WHO 
classification,3,4 and finally, 274 cases of histiocytic and den-
dritic neoplasms were selected.
We used the algorithm proposed by the Pathology Working 
Group of the International Lymphoma Epidemiology Consor-
tium (InterLymph).21,22 Clinicodemographic data were obtained 
from medical records at initial diagnosis and included informa-
tion on age; sex; anatomic disease occurrence site; radiologi-
cally measured tumor size; bone marrow biopsy and aspiration 
results; complete blood count results with differential counts, 
including those of white blood cells, hemoglobin, platelets, 
neutrophils, lymphocytes, and monocytes; blood chemistry 
results, including total protein, albumin, lactate dehydroge-
nase (LDH), erythrocyte sedimentation rate, C-reactive protein 
(CRP), blood urea nitrogen, creatinine, aspartate aminotrans-
ferase, alanine transaminase, total bilirubin, and alkaline phos-
phatase; and the Eastern Cooperative Oncology Group per-
formance score, Ann-Arbor stage, and B symptoms. Data on 
treatment modality and follow-up, including recurrence, death 
of disease, and/or last follow-up visit, were obtained from elec-
tronic medical records. This study was approved by the Insti-
tutional Review Board of Severance Hospital, Yonsei University 
College of Medicine (Seoul, South Korea) (Protocol ID, 4-2019-
0308). The requirement for informed consent was waived ow-
ing to the study’s retrospective design.
Statistical analysis
The χ2 test or Fisher’s exact test was conducted to analyze the 
significance of differences between variables. Overall survival 
(OS) was measured from the date of initial diagnosis to that of 
death or the last follow-up visit. Survival rates were determined 
using the Kaplan-Meier method and compared using the log-
rank test. A two-sided p value of <0.05 was considered statisti-
cally significant. All statistical analyses were performed using 
IBM SPSS 23 software for Windows (IBM Corp., Armonk, NY, 
USA).
RESULTS
Case distribution and demographic features of the 
subtypes
LCH was the most commonly observed subtype (56.6%, 155/ 
274), followed by dermal XG (35.0%, 96/274), HS (4.0%, 11/274), 
FDCS (1.8%, 5/274), DJG (1.1%, 3/274), ECD (0.7%, 2/274), 
IDCT (0.4%, 1/274), and IDCS (0.4%, 1/274). The distributions 







ECD, 2 (0.7%)IDCT, 1 (0.4%)
IDCS, 1 (0.4%)
Fig. 1. Distribution of histiocytic and dendritic cell neoplasms in Severance 
Hospital. LCH, Langerhans cell histiocytosis; XG, xanthogranuloma; HS, his-
tiocytic sarcoma; DJG, disseminated juvenile xanthogranuloma; ECD, Erd-
heim-Chester disease; FDCS, follicular dendritic cell sarcoma; IDCT, inde-
terminate dendritic cell tumor; IDCS, interdigitating dendritic cell sarcoma.
776
Histiocytic and Dendritic Cell Neoplasm
https://doi.org/10.3349/ymj.2020.61.9.774
images are shown in Supplementary Fig. 1 (only online).
Of the 155 LCH cases in our series, none were histologically 
compatible with LCS as per the WHO classification.2-4 Of the 
five FDCS cases, one showed disease in multiple sites of the 
retroperitoneum, liver, and iliac bone, suggesting the presence 
of inflammatory pseudotumor-like follicular/fibroblastic den-
dritic cell sarcoma. However, Epstein-Barr virus status could 
not be tested due to a lack of unstained slides transferred from 
an outside hospital. The five cases of juvenile xanthogranulo-
ma (histologically) showed proliferating CD68-positive foamy 
histiocytes derived from monocyte-derived macrophages, a 
histological and immunohistochemical finding compatible 
with the juvenile xanthogranuloma family. In addition, all five 
cases revealed systemic involvement compatible with systemic 
forms of the juvenile xanthogranuloma family. Among them, 
in two cases, the disease developed in late adulthood (age >60 
years) and involved multiple organs (the liver, spleen, spine, 
and lymph nodes in one case; the skin, lung, pericardium, 
bones, and lymph nodes in the other case), thus making them 
compatible with ECD. The remaining three cases involved one 
infant and two young adults aged 25 years who had systemic, 
deep visceral organ involvement of the mandible, spine, and 
nasopharynx. These clinical presentations make the three cas-
es compatible with DJG (Supplementary Table 1, only online). 
However, the follow-up period of ECD patients was short, and 
none of the patients experienced death. 
To compare the epidemiologic features of the subtypes, the 
patients were divided into five groups:2-4 dermal XG, DJG, ECD, 
and HS/FDCS/IDCS/IDCT as non-LCH sarcoma, and LCH. 
The demographic features of these five groups are summa-
rized in Supplementary Fig. 2 (only online). In the entire spec-
trum of histiocytic and dendritic neoplasms, the median age 
at diagnosis was 6 years (range, 0 to 77 years), and the female: 
male ratio was 1:1.4. A majority of the LCH cases occurred in 
pediatric patients (median age, 9 years), with 67.1% (111/155) 
of these patients aged younger than 15 years. The remaining 
histiocytic and dendritic cell neoplasm cases showed a wide 
age range. Dermal XG occurred in very early childhood (medi-
an age, 1 year). The ECD group showed the oldest patient age 
(median age, 64 years) (Supplementary Fig. 2A, only online). 
Generally, no sex-related predilection was noted (Supplemen-
tary Fig. 2B, only online). In most of the cases across the five 
groups, the affected organs were extranodal in nature (Supple-
mentary Fig. 2C, only online), such as the bone and skin, head 
and neck, gastrointestinal tract and abdomen, lung and thy-
mus, and brain and pituitary gland. About 13.5% (37/274) of 
the overall cases revealed multiorgan involvement. Specifical-
ly, 20.0% (31/155) of LCH cases, 100% (2/2) of ECD, and 22.2% 
(4/18, 3 HS and 1 FDCS) of non-LCH cases sarcoma showed 
multiorgan involvement (Supplementary Fig. 2D, only online). 
Advanced Ann-Arbor stage (stage III–IV) cases were frequent-
ly observed in the LCH (37/155, 23.9%), non-LCH sarcoma 
(4/18, 22.2%; three HS and one FDCS), and ECD (2/2, 100%) 
groups (Supplementary Fig. 2D, only online). In the entire 
spectrum of histiocytic and dendritic neoplasms, the median 
level of LDH was 245 IU/L (range, 136–2249 IU/L), and the me-
dian level of CRP was 5.5 mg/L (range, 0.2–107.4 mg/L). Among 
the cases for which laboratory data were available, elevated 
LDH levels were most frequently found in DJG, while elevated 
CRP levels were observed in all cases of ECD (Supplementary 
Fig. 2E, only online).
BRAF V600E mutation analysis was performed in 16 LCH 
cases, 3 DJG, 2 ECD cases, and one IDCT case. Of them, four 
cases of LCH (4/16, 25.0%) and one case of ECD (1/2, 50.0%) 
showed BRAF V600E mutation (Supplementary Fig. 2F, only 
online). LCH cases with BRAF V600E mutation showed no sig-
nificant difference in clinicopathologic and prognostic factors 
from those with wild-type BRAF (Supplementary Table 2, only 
online). Similarly, associations between the disease groups 
with respect to demographic and laboratory parameters were 
unremarkable.
Clinical outcomes 
The patients in our series underwent various treatments (Sup-
plementary Fig. 3A, only online). Among the 57 patients who 
underwent chemotherapy, 8 (14%) showed recurrence and 6 
(10.5%) died. Among 11 patients who underwent radiation 
therapy, 2 (18.2%) showed recurrence and 1 (9.1%) died. Among 
5 patients who underwent steroid therapy, no patient showed 
recurrence and 1 (20%) died. One patient underwent chemo-
radiation therapy, and this patient did not develop recurrence 
or die. Among the 200 patients who underwent diagnostic bi-
opsy and surgery without any adjuvant therapy, 1 patient, who 
had HS, developed recurrence and died. One patient with HS 
and 1 patient with LCH also died. The details are summarized 
in Supplementary Materials 2 (only online). The median follow-
up period was 14.4 months (range, 0–144 months); when der-
mal XG was excluded, it was 32.3 months (range, 0.03–144 
months). The follow-up periods of each group are summarized 
in Supplementary Fig. 3B (only online). During follow-up, 11 
(4.0%, 11/274) patients experienced recurrence, and 11 (4.0%, 
11/274) died of disease. Of the 11 patients with recurrence, sev-
en (4.5%, 7/155) had LCH, three (27.3%, 3/11) had HS, and one 
(20%, 1/5) had FDCS (Supplementary Fig. 3C, only online). Of 
the 11 patients who died of disease, five (3.2%, 5/155) showed 
LCH, five (45.5%, 5/11) showed HS, and one (20%, 1/5) showed 
FDCS (Supplementary Fig. 3D, only online). The clinicopath-
ologic features of the patients who developed recurrence and/
or died are summarized in Supplementary Table 3 (only online).
When the Kaplan-Meier survival analysis was performed to 
compare the prognosis of disease subtypes excluding dermal 
XG, which has a benign prognosis, the OS rates differed across 
the subtypes. The non-LCH sarcoma group showed the worst 
OS values, compared to the DJG, ECD, and LCH groups (p<0.001, 
respectively) (Fig. 2).
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DISCUSSION
In the present series, we comprehensively described the epi-
demiologic features of histiocytic and dendritic cell neoplasms. 
The most common subtype was LCH, consistent with previous 
studies.2-4 Among the non-LCH type sarcomas, HS showed the 
highest prevalence, followed by FDCS. IDCS and IDCT were 
very rarely observed. To our best knowledge, this may be the 
first comprehensive study focusing on the epidemiologic char-
acterization of the entire spectrum of histiocytic and dendritic 
cell neoplasms in South Korea according to recent WHO clas-
sification.
Dermal XG is a benign disease entity in the juvenile xantho-
granuloma family. DJG and ECD do not have an ICD-O-3 code 
pointing to histologically malignant behavior or are designat-
ed as “uncertain whether benign or malignant” according to 
ICD-10 or -11.5,6 However, the 2016 WHO classification cate-
gorized ECD as a malignancy.3 The diagnosis of dermal XG, 
DJG, and ECD as individual entities via histology alone is dif-
ficult, as there is no histologic difference between the usual 
dermal type and systemic type of juvenile xanthogranuloma 
that shows proliferating CD68-positive foamy histiocytes de-
rived from monocyte-derived macrophages.1-3 Therefore, we 
included the entire spectrum of juvenile XG and comprehen-
sively analyzed it to characterize the epidemiologic features of 
each entity. Dermal XG was the second most prevalent entity 
following LCH, while DJG and ECD were relatively rarer.
Few comprehensive epidemiologic series to date have in-
cluded a large number of cases reflective of the overall spec-
trum of histiocytic and dendritic cell neoplasm. Thus, it may 
be difficult to compare the subtype proportions observed in 
our series to those in other series. A recent epidemiologic sin-
gle-center study of 32 histiocytic and dendritic cell neoplasm 
cases7 showed that the most common type was LCH, followed 
by HS, FDCS, IDCS, and IDCT, consistent with our study. 
Data on the general epidemiologic characteristics in our se-
ries were in agreement with those described in the literature.2-4 
Histiocytic and dendritic cell neoplasms generally occurred in 
childhood, despite the wide age distribution range, as previ-
ously noted.2-4 This is due to the large proportion of cases with 
LCH and dermal XG, which are well-known pediatric malig-
nancies. However, the non-LCH sarcoma group, including HS, 
FDCS, IDCS, and IDCT, as well as ECD, tended to occur in late 
adulthood.2-4 A majority of the histiocytic and dendritic cell 
neoplasms occurred in extranodal sites like the bone and skin 
rather than the lymph nodes, and multiorgan involvement was 
also not uncommon in the LCH, non-LCH sarcoma (HS/FDCS/ 
IDCS/IDCT), and ECD groups. Cases with advanced Ann-Ar-
bor stage (stage III–IV) were also frequently observed in the 
LCH, non-LCH sarcoma, and ECD groups. Elevated LDH lev-
els were frequently noted, especially in the LCH cases.
Several studies have focused on BRAF V600E mutations in 
histiocytic and dendritic cell neoplasms, and the biologic and 
prognostic implications of these have been suggested in such 
tumours.3,19,23-26 In our LCH cases, BRAF V600E mutations were 
noted in 25% (4/16) of the tested cases, and there was no sig-
nificant difference in clinicopathologic and prognostic factors 
between LCH cases with the mutation and those with wild-type 
BRAF. Most of the samples in the LCH group included the bone 
and were decalcified in the tissue preparation processes; there-
fore, we could not comprehensively perform BRAF V600E mu-
tation tests. Although such cases account for only a small por-
tion (16/155, 10.3%) of LCH and may not represent the overall 
number of LCH cases in our series, this mutation rate was low-
er than that observed previously (57%).23 A recent meta review 
of 653 LCH cases showed an overall BRAF V600E mutation in-
cidence of 48.5%.24 In a study using 48 LCH samples from a 
Western population, the BRAF V600E mutation incidence rate 
was 48%; however, the mutation exhibited no significant im-
plications in terms of clinicopathologic variables or patient 
prognoses.24 Our findings are similar to those of another study 
that tested 27 LCH cases from the same country-based popu-
lation and found a relatively low rate (22.2%, 6/27) of mutation 
and a lack of clinicopathologic significance for BRAF V600E 
mutation status.25 In a recent East Asian study, no BRAF V600E 
mutations were noted.19 This may be attributed to differences 
in the BRAF testing methods or technical differences, as well 
as ethnicity-related and regional differences. Although BRAF 
V600E mutation status may predict responses to targeted 
treatment, the clinical and prognostic implications of this mu-
tation are still controversial, and further research is required.24 
None of the three DJG cases showed BRAF V600E mutation, 
while one of the two ECD cases showed the mutation. Despite 
the small number of cases in our series, this result is consistent 
with previous findings.24,25,27
Immunohistochemical testing using the BRAF VE1 antibody28 
in this study failed to detect positive immunoexpression in the 
































Fig. 2. Kaplan-Meier survival analysis. The HS/FDCS/IDCS/IDCT group 
showed worse overall survival rates than the DJG, ECD, and LCH groups 
(p<0.001, respectively). HS, histiocytic sarcoma; FDCS, follicular dendritic 
cell sarcoma; IDCS, interdigitating dendritic cell sarcoma; IDCT, indeter-
minate dendritic cell tumor; LCH, Langerhans cell histiocytosis; DJG, dis-
seminated juvenile xanthogranuloma; ECD, Erdheim-Chester disease.
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histochemistry for BRAF V600E mutation has been reported to 
have low sensitivity and specificity in LCH or other histiocytic 
and dendritic cell neoplasms.29-31 Therefore, further validation 
is required to elucidate the accuracy of immunohistochemis-
try in determining BRAF V600E mutation status in histiocytic 
and dendritic cell neoplasms.
Our outcome analyses showed that most of the histiocytic 
and dendritic cell neoplasms exhibit indolent clinical behav-
iours.2-4 The frequency of disease recurrence or death of disease 
was not higher than 10%. None of the dermal XG cases revealed 
death of disease, supporting this entity’s benign nature.2-4 The 
rate of recurrence or death of disease was also low in the DJG 
and ECD cases, suggesting the uncertainty of their clinical and 
biological nature for malignancy.5,6 As expected,2-4 the HS cas-
es showed relatively high recurrence and death rates. Of the 
five FDCS cases, one revealed recurrence and death. The non-
LCH sarcoma group showed the worst OS rate, compared to 
the LCH and DJG and ECD groups. Therefore, more accurate 
diagnoses and additional treatment may be needed for non-
LCH sarcoma, especially HS cases. Despite the limitations as-
sociated with the use of single hospital-based data, our series 
may be used as a surrogate of population-based data, and our 
findings may be useful in the provision of more accurate diag-
noses and formulation of more appropriate patient manage-
ment strategies.
In summary, the LCH subtype appears to be the most com-
mon histiocytic and dendritic cell neoplasm. Among non-LCH 
type sarcomas, HS was the most prevalent, followed by FDCS. 
The other subtypes were rare. Generally, these tumors oc-
curred in childhood, although non-LCH sarcoma and ECD oc-
curred in late adulthood. Our findings indicate that outcomes 
may differ among patients with the same histiocytic and den-
dritic cell neoplasm subtype, because some may have adverse 
prognostic factors, such as multiorgan involvement, elevated 
LDH levels, and advanced Ann-Arbor stage, while others may 
not. BRAF mutations were noted in the LCH and ECD cases, 
although the prognostic implications thereof remain uncer-
tain. Most of the patients in our series showed indolent clini-
cal behaviors, while the non-LCH sarcoma group, especially 
HS cases, showed unfavorable outcomes. 
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